The Era of PARP Inhibition in Cancer Management - Patient Selection and Deciding When to Use in Treatment

New reporting suggests obesity and diffuse large B-cell lymphoma (DLBCL) have shared genetic risk factors.

Sadie Dobrozsi, MD, of Evolent, discusses how predictive genomics is pushing cancer care into a new era of personalization

Early research has identified several antigens that could help facilitate the use of chimeric antigen receptor T cells in small cell lung cancer.

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

Biomarkers like neutrophil-to-lymphocyte ratio could help predict treatment response to immune checkpoint inhibitors in certain patients with soft tissue sarcoma.

Second primary malignancies in patients with small cell lung cancer are often misdiagnosed as distant metastases.